Search Videos by Topic or Participant
Browse by Series:

Treatments for ALK-Positive NSCLC

Panelists: Roy S. Herbst, MD, PhD, Yale; Mark A. Socinski, MD, University of Pittsburgh;Thomas E. Stinchcombe, MD, UNC; Anne S. Tsao, MD, MD Ande
Published: Saturday, May 02, 2015
For High-Definition, Click

 
In first-line and second-line phase III trials of individuals with ALK-rearranged, non-small cell lung cancer (NSCLC), crizotinib was shown to be more active than standard chemotherapy, states Mark A. Socinski, MD. Crizotinib is orally administered, well tolerated, and the preferred option for initial treatment of patients with ALK-positive NSCLC. Toxicities include vision abnormalities and nausea.

Ceritinib is a second-generation ALK inhibitor that is 20 to 50 times more potent than crizotinib, says Socinski. This agent is active in individuals who were previously treated with ALK inhibition and developed resistance or progressed, as well as individuals who are treatment-naïve. Its current indication is in second-line treatment, following crizotinib exposure.
Slider Left
Slider Right
For High-Definition, Click

 
In first-line and second-line phase III trials of individuals with ALK-rearranged, non-small cell lung cancer (NSCLC), crizotinib was shown to be more active than standard chemotherapy, states Mark A. Socinski, MD. Crizotinib is orally administered, well tolerated, and the preferred option for initial treatment of patients with ALK-positive NSCLC. Toxicities include vision abnormalities and nausea.

Ceritinib is a second-generation ALK inhibitor that is 20 to 50 times more potent than crizotinib, says Socinski. This agent is active in individuals who were previously treated with ALK inhibition and developed resistance or progressed, as well as individuals who are treatment-naïve. Its current indication is in second-line treatment, following crizotinib exposure.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x